NetworkNewsBreaks

TuesdayMay 27, 2025 11:20 am

NetworkNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Declares US$0.0125 Semi-Annual Dividend 

Silvercorp Metals (TSX: SVM) (NYSE American: SVM)  announced its Board of Directors has declared a semi-annual dividend of US$0.0125 per share, payable on or before June 26 to shareholders of record as of June 6. The dividend is designated as an eligible dividend for Canadian tax purposes. The company noted that future dividends will be determined at the Board’s discretion based on market conditions, financial performance, and other relevant factors.  To view the full press release, visit https://nnw.fm/QMMI4  About Silvercorp  Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and growth…

Continue Reading

TuesdayMay 27, 2025 10:15 am

NetworkNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Advances 6.9 MW Community Solar Project in Nova Scotia

Disseminated on behalf of SolarBank Corporation  SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will develop the 6.9 MW DC Brooklyn solar project in Nova Scotia under Canada’s first Community Solar Program. Owned by AI Renewable Fund, the $13.9 million project will be built in partnership with local firm Trimac Engineering. The program supports Nova Scotia’s goal of reaching 80% renewable energy by 2030 and net-zero by 2035. SolarBank will oversee interconnection, permitting, and design through 2025, with construction expected to begin in spring 2026. The company also disclosed a shares-for-services agreement with an independent advisor valued at up to…

Continue Reading

TuesdayMay 27, 2025 9:20 am

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Advances Toward Production With Delivery of Gravity Separation Circuit

ESGold (CSE: ESAU) (OTCQB: ESAUF) announced the successful delivery of Humphrey spiral concentrators to its Montauban site in Quebec, completing the full gravity separation circuit essential for near-term production. The system will process up to 1,000 tonnes per day of historic tailings into a marketable mica concentrate while also recovering gold and silver. CEO Paul Mastantuono described the milestone as a tangible step toward ESGold’s transition to producer status, with construction progressing and first production targeted by year-end 2025. An updated preliminary economic assessment is expected soon. To view the full press release, visit https://nnw.fm/kcUb1 About ESGold Corp. ESGold Corp. (CSE: ESAU)…

Continue Reading

TuesdayMay 27, 2025 9:10 am

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast

Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s focus on transdermal drug delivery systems, particularly in the underserved area of pain management. Sheridan emphasized the impact of the opioid crisis on patient access to effective medications, noting that the stigma and liability concerns surrounding opioids have left many pain patients without adequate care. He introduced AVERSA(TM), Nutriband’s internally developed platform designed to deter abuse of opioid patches by…

Continue Reading

FridayMay 23, 2025 3:45 pm

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) Unveils New Exploration Target, Boosting Montauban Project Potential

ESGold (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D), a fully permitted, pre-production resource company on a clear path to near-term gold and silver production, recently reported the identification of a significant geophysical anomaly in the southwest portion of its Montauban Project in Quebec. “According to a company press release, internal analysis of historical VTEM (Versatile Time Domain Electromagnetic) survey data and drill records has highlighted this area as a high-priority exploration target,” reads a recent article. “The zone, which has not yet been tested by drilling, displays a strong combination of electromagnetic conductivity and magnetic response, a dual signal often associated…

Continue Reading

FridayMay 23, 2025 2:45 pm

NetworkNewsBreaks – Why ONAR Holding Corp. (ONAR) Is ‘One to Watch’

ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network focused on delivering integrated, AI-driven solutions to accelerate revenue growth for its clients. “Through an agile agency network specializing in performance marketing, full-service healthcare marketing, experiential marketing, and technology incubation, ONAR provides best-in-class services to a growing roster of clients worldwide,” reads a recent article discussing the company. “Built on a foundation of innovation and operational excellence, ONAR’s vision is to redefine marketing services by leading with technological advancement. ONAR’s strategic growth model focuses on growing and acquiring proven agencies under one umbrella to deliver superior service offerings…

Continue Reading

FridayMay 23, 2025 12:34 pm

NetworkNewsBreaks – Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025 

Beam Therapeutics (NASDAQ: BEAM), a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated data from its BEACON Phase 1/2 trial of BEAM-101 at the European Hematology Association 2025 Congress, June 12-15 in Milan. BEAM-101 is an investigational, one-time ex vivo cell therapy targeting severe vaso-occlusive crises in sickle cell disease (SCD). The new data, covering safety and efficacy outcomes in 17 patients, will be highlighted during multiple poster sessions on June 13, underscoring BEAM-101’s potential to provide a durable treatment by addressing the root cause of SCD. Additional presentations will explore biomarkers, manufacturing advances,…

Continue Reading

FridayMay 23, 2025 9:28 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Expands Global Reach with Juve Stabia Serie A Playoff Match Streaming in U.S., Canada and UK 

Brera Holdings (NASDAQ: BREA) announced that its Italian Serie B club S.S. Juve Stabia will stream its second Serie A playoff semifinal match against Cremonese live and free on Sunday, May 25, via Destination Calcio TV in the U.S., Canada and the UK. This follows Juve Stabia’s 2-1 win in the first leg. The international broadcast underscores Brera’s strategy to grow Juve Stabia’s global visibility through media access, fan engagement, and its multi-club ownership model. Executive Chairman Daniel McClory said the exposure builds the club’s audience in key markets and highlights its compelling underdog narrative following its upset of City…

Continue Reading

FridayMay 23, 2025 9:10 am

NetworkNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports $58.2 Million Net Income for Fiscal 2025, Revenue Up 39 Percent

Silvercorp Metals (TSX: SVM) (NYSE American: SVM)  reported $58.2 million in net income for the fiscal year ended March 31, 2025, up 60% from the prior year, on revenue of $298.9 million, a 39% increase. Fiscal 2025 production included 7.5K oz of gold, 6.9M oz of silver, 62.2M lb of lead and 23.3M lb of zinc. The company also posted adjusted earnings of $75.1 million or $0.37 per share, with cash flow from operations reaching $138.6 million. In Q4, Silvercorp reported a net loss of $7.6 million due to a $20.6 million non-cash derivative charge, but adjusted quarterly net income came…

Continue Reading

ThursdayMay 22, 2025 3:55 pm

NetworkNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,’ the company reported. The study results suggest that the treatment may be highly effective in reducing…

Continue Reading